13F Holdings
中文EN

EVMN Evommune, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 2044725 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-100.0%
TTM net income YoY-84.4%
TTM EPS YoY131.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-331.4%
ROA-62.3%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets9.7%
Debt / equity0.00x
Current ratio8.52x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-12.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$13.00M$7.00M
R&D expense$74.04M$64.24M
SG&A expense$20.03M$12.77M
Operating income-$81.07M-$70.01M
Pretax income-$68.87M-$68.31M
Income tax$0$0
Net income-$68.87M-$66.81M
EBITDA-$80.47M-$69.51M
EPS (basic)-11.22-45.29
EPS (diluted)-11.22-45.29
Weighted avg. shares (diluted)6.14M1.51M
Balance sheet
Cash & equivalents$44.06M$16.46M
Short-term investments$105.14M$55.78M
Current assets$153.48M$73.99M
PP&E, net$994,000$1.33M
Total assets$224.95M$76.06M
Current liabilities$17.91M$27.98M
Total liabilities$19.38M$28.52M
Shareholders' equity$205.57M-$144.24M
Shares outstanding31.52M1.55M
Cash flow statement
Operating cash flow-$76.44M-$58.20M
Capital expenditure$235,000$88,000
Free cash flow-$76.68M-$58.28M
Investing cash flow-$115.31M-$3.99M
Financing cash flow$220.76M$49.42M
Depreciation & amortization$600,000$500,000
Stock-based compensation$5.86M$1.72M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.